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Abstract
Purpose: To assess bladder and rectum doses in relation to body mass index ofpatients undergoing high dose rate brachytherapy for the treatment of carcinomaof the cervix. Methods: The cohort consists of fifty subjects with carcinoma of theuterine cervix presented with grade II and III. Patient’s height and weight wasmeasured before the insertion of applicator in situ. Body mass index (BMI) of thepatient was calculated in accordance to World Health Organization definition(weight in Kg/ height in m2). Adequacy of position and orientation of the applicatorwas confirmed with the help of orthogonal X-ray images and the same weretransferred to the treatment planning system (TPS) to generate treatment plan.Prescription doses were optimized to Point A and to reference lines placed at 0.5cm apart from the surface of ovoids. The following dose reference points wereidentified on orthogonal x-ray images for analysis using the rectal marker andFoleys bulb inflated with radio opaque dye Rectal points at the level of femoralheads (RL) and pubis symphysis (RLP), Anorectum Junction (AR Jn) point andRectosigmoid (RS) point and Bladder point (BL). Pearson regression analysis wasused to analyze data from TPS. Results: The mean BMI was 22.7 kg/m2 andaverage age was 49.9 years. Analysis showed that RL point dose and BMI wereinversely correlated with a coefficient -0.45 (p = 0.001). The trend continued alongthe rectal tube in cranio-caudal direction, as RLP and AR Jn points showedinversion co-efficiency with increase in BMI,-0.48 (p < 0.01) and -0.51 (p < 0.01)respectively. Bladder point showed weak positive correlation to BMI, 0.12 (p =0.38). Conclusion: Significant rectal dose reduction is observed with increase inBMI. Bladder dose did not show statistically significant correlation with BMI. Basedon the findings, BMI constitutes a confounding factor in the treatment of carcinomaof cervix.
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1. IntroductionCarcinoma of the cervix is radiosensitive and radiation isused in all stages and where surgery is not possible.Intracavitary brachytherapy (ICBT) along with externalbeam radiotherapy (EBRT) forms an essentialcomponent in the management. It provides hightherapeutic index by delivering a high dose to theprimary cervical lesion and lower doses to adjacent
organs, resulting in increased local control and survivalwithout increase in toxicity.1-4 Body mass index (BMI), ameasure of body weight in relation to height, is relatedto numerous morbidities. These include diabetes, highblood pressure, hyperlipidemia and psychiatricwellness. BMI is also linked to cancers of the colon andthe breast.5-6 Authors reported that link between cancer
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risk and BMI is likely to involve sex and growthhormones and effects of nutrition.7-8Brachytherapy is an advanced cancer treatmentmodality, which uses radioactive seeds or sourcesplaced in or near the tumor itself, giving a high radiationdose to the tumor while reducing exposure to organs atrisk. ICBT procedure involves placing the applicator inthe uterus in situ to deliver radiation to cervix. Bladder,rectum and bowels are organs at risk (OAR), radiationdoses to which should be considered. The accuratecalculation of dose to organ at risk is a crucial objectivein treatment planning. This is particularly true in thecase of high dose rate (HDR) brachytherapy.9Several studies evaluated radiation induced toxicities toOARs i.e., bladder, rectum and bowel using dosimetricparameters.10-12 Nora et al.13 studied effects of BMI oncomplications and survival outcomes in patientsundergoing curative chemoradiotherapy for cervicalcarcinoma. Jihoon et al.14 studied dependence of rectaldoes on BMI of the patient underwent ICBT with theapplication of tandem and ring applicator.Brachytherapy sources exhibit steep dose fall off withdistance and this phenomenon is utilized to deliver highdose to tumor while sparing surrounding normal tissues.If rectum and bladder distance increases from theapplicator in situ due to deposition of fat i.e., the case ofhigher BMI, there is a reduction in dose to bladder andrectum. The purpose of the present work is to analyzerelation between BMI and bladder and rectal doses inthe patients who underwent ICBT for treatment ofcarcinoma of the cervix with tandem and ovoidapplicator. This study adds to the literature the effect ofBMI as a confounding factor in the treatment ofcarcinoma of cervix and would be of help for furtherinvestigations.
2. Methods and MaterialsThe sample consists of fifty patients with carcinoma ofthe uterine cervix of grade II and grade III with ageranging from 26 years to 70 years. All patients wererecruited with the approval of hospital ethics committee.Standard Henschke applicator set (Mick Radio-NuclearInstruments, Inc., NY, USA) with different tandemlengths and ovoid diameters was used depending on thepatients’ anatomy. Tandem lengths of 5 cm to 6 cm andovoid diameters from 2 cm to 3 cm were employed.Height and weight of the patient was recorded prior tothe insertion of applicator and BMI was calculated usingWorld Health Organization definition i.e., weight in Kg/height in m2. Patients were imaged on acuity physicalsimulator (Varian, Palo Alto, CA, USA). Orthogonal X-rayimages were obtained to confirm the adequacy ofposition of applicator in anteroposterior and lateral
directions at gantry angles 0˚ and270˚ respectively. Thesame were transferred to the Brachyvision treatmentplanning system (TPS) Version 7.3 (Varian MedicalSystems, Palo Alto, CA, USA) via Aria network (VarianMedical Systems, Palo Alto, CA, USA) for planning.Treatment regime for the treatment of cervical cancerconsists of concurrent weekly cisplatin chemotherapy of40 mg/m2 in 5 cycles and external beam radiationtherapy of 50 Gycombined with 3 sessions of HDRBrachytherapy with dose per fraction ranging from 6 Gyto 7 Gy. First fraction of HDR Brachytherapy starts aftera dose of 30 Gy delivered by external beam radiationtherapy.Prescribed dose is optimized to Point A and to thereference lines placed at 0.5 cm apart from the surface ofovoids. The following dose reference points wereidentified on orthogonal x-ray images for analysis: pointA, bladder point (BL), rectal points (RL, RLP), anorectumjunction (AR Jn) point and rectosigmoid (RS) points.International Commission on Radiation Units andMeasurements (ICRU 38) recommendations werefollowed to identify bladder point. In addition two morepoints were digitized at the superior and inferior surfaceof the Foley bulb and named as BLS and BLI (Figure 1).Rectal tube with dummy marker wire was used to locatethe modified rectal point. It was identified at a point onthe rectal marker wire in lateral view at the level of (aline joining) the centers of the right and left femoralheads in anterio-posterior view. Two additional pointswere marked at 1 cm on either side of the modifiedrectal point in cranio-caudal direction. RLP point waslocated on rectal tube at the inferior portion of pubicsympysis. An AR Jn point mimics the anorectal junctionis marked on the rectal tube at the intersection of a lineconnecting pelvic ischial tuberosity. RS point wasmarked at the anterior surface of S1-S2 junction inlateral view and at the same level on the midline inanteroposterior view. Regression analysis was carriedout to find out relation between BMI and dose at definedreference points.
3. ResultsData of doses at defined reference points from TPS wasanalyzed and following results were observed. Patientswere classified as per the definition of BMI given byWHO. Out of fifty patients 2 were morbidly obese, 5were obese, 7 were overweight, 27 were normal and 9were under weight. The mean BMI was 22.7 kg/m2 witha range from 13.1 kg/m2 to 35.7 kg/m2. The average agewas 49.7 years and range from 26 to 70 years. The meandose to bladder point was 6.36 Gy with a range from 3.9Gy to 7.9 Gy.
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Figure 1: Orthogonal X-ray radiographs.
Table 1: Correlation coefficients and dose characteristics.Dose in cGy 95% CI p-value CCMean Range SD lower UpperBladder Point 636 394.2‒787.2 92.9 609.3 662.7 0.38 0.13Rectal Point 512.8 314.4 ‒702 110.9 481.0 544.7 0.001 -0.45RLP 242.8 100.3‒ 435.4 81.6 219.4 266.3 <0.001 -0.48AR Jn 121.2 60.2‒211.1 32.2 112.0 130.4 <0.001 -0.51RS Point 202.6 76.8‒397.5 80.2 179.6 225.7 0.34 0.13SD = standard deviation; CI= confidence interval: CC= Correlation coefficientRLP: Rectal point at the level of Pubis Symphysis, AR Jn: Anorectal Junction, RS Point: Recto Sigmoid Point.
Figure 2: Regression plot of BMI vs Dose to ICRU Bladderpoint. Figure 3: Regression plot of BMI vs Dose to points onRectal marker.
Bladder vs BMI


















BMI vs Dose to points on Rectal Marker
y = -9.1714x + 721.21
R2 = 0.204
y = -7.1111x + 404.45
R2 = 0.2264






















4 Talluri et al.: Body mass index versus bladder and rectal doses International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Talluri et al. ISSN 2330-4049
Pearson regression analysis was used to studycorrelation of BMI and dose to different points i.e.,Bladder point, rectal points, RS point and AR point.Bladder point showed weak positive correlation, 0.13(Table 1) to BMI (Figure 2). Analysis showed that RLpoint dose and BMI were inversely correlated with acoefficient -0.45 (p = 0.001) (Figure 3). The trendcontinued along the rectal tube in craniocaudal directionas RLP point and AR Jn point negatively correlated, -0.48with -0.51 (Table 1)respectively with BMI. Nocorrelation was observed between RS point and BMIwith coefficient 0.13 (p = 0.34).
4. DiscussionThe aim of radiotherapy is to deliver high dose to tumorwhile sparing surrounding normal tissue by notexceeding the tolerance doses. Brachytherapy sourcesare characterized by steep dose gradients15-16 whichresults in sparing normal tissues. HDR brachytherapyinvolves delivery of higher radiation doses over a shortperiod of time and carries risk of acute and latecomplications particularly to rectum and bladder as anyother radiation technique. There are many factors thatcontribute to acute and late complications like dose perfraction, total dose, treatment time and patientcharacteristics. Potential factors that may affecttreatment complications are co-morbidities, pelvicsurgical history, tobacco and anticoagulationmedication.In this study doses to OARS are categorized based on theBMI of the patients. Treatment plans were generated todeliver prescribed dose to point A (and reference linesto ovoids without checking for violation of dose to organat risk). Treatment planning is carried out on 2D planarimages and the dosimetry of various dose referencepoints related OARs is studied. This study is carried outto correlate and establish the dosimetric results fromearlier studies. Jihoon et al.14 studied extensively theimpact of BMI on rectal complications in the case oftreatment of locally advanced carcinoma of the cervix.The study found that there was a negative correlationbetween dose to 2 cc rectum and increase in BMI.Authors did not find any association of BMI and acute orlate morbidity of rectum even when controlling forconfounders such as age, smoking, hypertension,anticoagulants and diabetes. The same is observed inour study, different rectal points RLS, RLI and RLP withcorrelation coefficients -0.34 (p = 0.150), -0.48 (p =0.001) and - 0.47 (p = 0.001) respectively, showingreduction in dose with increase in BMI. In contrast tothis Kizer et al.17 showed patients with higher BMI tohave lower rectal toxicities (compared to lower BMI)undergoing chemoradiation treatment. In another studyBoyle et al.18 studied body mass index and dose to organat risk during vaginal cuff brachytherapy with vaginalcylinders and concluded that women with higher BMI
received lower bladder and small bowel dose comparedto patients with lower BMI. However, we did not findstatistical significance in correlation of BMI and bladderdose. This may be due to applicator type used andsurrounding tissue. In addition to the dose to bladder atICRU Bladder point we have studied dose at two otherdose points (Figure 1) BLS and BLI, located at superiorand inferior ends of the Foleys bulb. Doses at these twopoints no way correlated to BMI of the patient,correlation coefficients were 0.1 (p = 0.4) and -0.08 (p =0.5) respectively. Gastrointestinal dose parametersstudied in earlier studies14,18 showed weak or nocorrelation with BMI, which is in concurrence with ourstudy with RS Point showing weak positive correlationto BMI, i.e., 0.13 (p = 0.34).
5. ConclusionThis study concludes that dose along the rectumdecreases with increase in BMI. We did not findstatistical significance in correlation of BMI and bladderdose. Rectosigmoid point showed weak positivecorrelation. This study is in strong coherence with thecurrent literature.
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